Integrated system of the tailor-made cancer treatment based on the expression profiling and bioinformatic analyses

基于表达谱和生物信息分析的定制癌症治疗集成系统

• 批准号: 15390181
• 负责人: TAKAHASHI Takashi
• 金额: $ 8.06万
• 依托单位: Nagoya University (2004-2005)Aichi Cancer Center Research Institute (2003)
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2003
• 资助国家: 日本
• 起止时间: 2003 至 2005
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15390181/
• 关键词: Expression profiling; Microarray; Bioinformatics; Proteomics; Mass spectrometry; 発現プロファイリング

In this study, we have carried out highly sophisticated genomics and proteomics analyses of surgically resected cases of lung cancer, which has been the number one cause of cancer deaths in Japan, in order to establish the foundation for the integrated system of the tailor-made cancer treatment. As a result, we were able to show the presence of expression-profile-defined heterogeneity of pulmonary adenocarcinomas, which appeared to be correlated well with the status of genetic alterations and postoperative clinical behaviors such as prognosis. Furthermore, the newly proposed classification could distinguish a subset of patients, which most likely benefit from adjuvant molecular targeted therapy against EGFR-mediated signaling. In addition, we were able to establish the foundation for future studies on the applied proteomics of blood specimens such as serum. These findings should aid further development of genomics and/or proteomics-based approach towards the tailor-made medicine to conquer this devastating illness.

在本研究中，我们对手术切除的肺癌病例进行了高度复杂的基因组学和蛋白质组学分析，这是日本癌症死亡的头号原因，以便为定制癌症治疗的综合系统奠定基础。因此，我们能够显示存在表达谱定义的肺腺癌异质性，这似乎与遗传改变的状态和术后临床行为如预后密切相关。此外，新提出的分类可以区分一部分患者，这些患者最有可能受益于针对EGFR介导的信号传导的辅助分子靶向治疗。此外，我们能够建立一个基础，为未来的研究应用蛋白质组学的血液标本，如血清。这些发现应该有助于进一步发展基因组学和/或蛋白质组学为基础的方法，以量身定制的药物来征服这种毁灭性的疾病。

项目成果

The ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features.

ASH1基因是具有神经内分泌特征的肺癌的特异性治疗靶点。

• 发表时间: 2005
• 期刊: Cancer Research 65
• 作者: Osada;H.;et al.
• 通讯作者: et al.

Histone modification in the TGFβRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.

TGFβRII 基因启动子中的组蛋白修饰及其对肺癌细胞系中 HDAC 抑制剂反应的意义。

• 发表时间: 2005
• 期刊: Molecular Carcinogenesis 44
• 作者: Osada;H.;et al.
• 通讯作者: et al.

Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors

• DOI: 10.1200/jco.2005.03.8224
• 发表时间: 2006-04-10
• 期刊: JOURNAL OF CLINICAL ONCOLOGY
• 影响因子: 45.3
• 作者: Takeuchi, T;Tomida, S;Takahashi, T
• 通讯作者: Takahashi, T

Konishi, H., et al.: "Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer."Oncogene. 22. 1892-1905 (2003)

Konishi, H. 等人：“对应于人类肺癌远端 17p13.3 候选肿瘤抑制基因座的纯合缺失区域的详细表征。”癌基因。

Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction

• DOI: 10.1200/jco.2004.04.109
• 发表时间: 2004-03-01
• 期刊: JOURNAL OF CLINICAL ONCOLOGY
• 影响因子: 45.3
• 作者: Endoh, H;Tomida, S;Mitsudomi, T
• 通讯作者: Mitsudomi, T